Sumitomo Life Insurance Co. Sells 722 Shares of The Cooper Companies, Inc. $COO

Sumitomo Life Insurance Co. cut its position in The Cooper Companies, Inc. (NASDAQ:COO) by 6.7% in the second quarter, HoldingsChannel.com reports. The firm owned 10,028 shares of the medical device company’s stock after selling 722 shares during the period. Sumitomo Life Insurance Co.’s holdings in Cooper Companies were worth $714,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Zions Bancorporation National Association UT bought a new position in Cooper Companies in the first quarter worth about $33,000. GKV Capital Management Co. Inc. acquired a new position in shares of Cooper Companies during the first quarter valued at about $40,000. J.Safra Asset Management Corp increased its holdings in shares of Cooper Companies by 204.8% during the second quarter. J.Safra Asset Management Corp now owns 506 shares of the medical device company’s stock valued at $36,000 after acquiring an additional 340 shares in the last quarter. Assetmark Inc. increased its holdings in shares of Cooper Companies by 357.8% during the second quarter. Assetmark Inc. now owns 618 shares of the medical device company’s stock valued at $44,000 after acquiring an additional 483 shares in the last quarter. Finally, Larson Financial Group LLC increased its holdings in shares of Cooper Companies by 1,071.0% during the first quarter. Larson Financial Group LLC now owns 726 shares of the medical device company’s stock valued at $61,000 after acquiring an additional 664 shares in the last quarter. 24.39% of the stock is currently owned by institutional investors.

Cooper Companies Price Performance

Shares of NASDAQ COO opened at $69.91 on Monday. The business’s 50 day moving average price is $69.37 and its 200 day moving average price is $72.95. The firm has a market cap of $13.90 billion, a P/E ratio of 34.44, a P/E/G ratio of 1.83 and a beta of 1.02. The Cooper Companies, Inc. has a 52 week low of $61.78 and a 52 week high of $107.84. The company has a quick ratio of 1.24, a current ratio of 2.12 and a debt-to-equity ratio of 0.29.

Cooper Companies (NASDAQ:COO) last issued its earnings results on Wednesday, August 27th. The medical device company reported $1.10 EPS for the quarter, beating analysts’ consensus estimates of $1.07 by $0.03. Cooper Companies had a return on equity of 9.82% and a net margin of 10.08%.The firm had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same quarter in the prior year, the firm earned $0.96 earnings per share. Cooper Companies’s revenue for the quarter was up 5.7% on a year-over-year basis. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. On average, sell-side analysts expect that The Cooper Companies, Inc. will post 3.98 earnings per share for the current year.

Cooper Companies announced that its board has approved a stock buyback program on Wednesday, September 17th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical device company to reacquire up to 15.4% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s management believes its stock is undervalued.

Insiders Place Their Bets

In related news, CEO Albert G. White III acquired 10,000 shares of the stock in a transaction on Friday, September 5th. The shares were acquired at an average price of $68.39 per share, for a total transaction of $683,900.00. Following the transaction, the chief executive officer owned 226,151 shares in the company, valued at approximately $15,466,466.89. This trade represents a 4.63% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Daniel G. Mcbride acquired 3,000 shares of the stock in a transaction on Tuesday, September 2nd. The stock was bought at an average price of $65.04 per share, for a total transaction of $195,120.00. Following the transaction, the chief operating officer owned 63,120 shares in the company, valued at approximately $4,105,324.80. This represents a 4.99% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have bought 17,975 shares of company stock worth $1,216,346. Corporate insiders own 1.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on COO. Wells Fargo & Company cut their price objective on shares of Cooper Companies from $93.00 to $72.00 and set an “overweight” rating on the stock in a report on Thursday, August 28th. BNP Paribas Exane upgraded shares of Cooper Companies from a “neutral” rating to an “outperform” rating and set a $92.00 price objective on the stock in a report on Tuesday, July 22nd. BNP Paribas upgraded Cooper Companies from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 22nd. Stifel Nicolaus dropped their target price on Cooper Companies from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday, August 28th. Finally, The Goldman Sachs Group set a $64.00 target price on Cooper Companies and gave the company a “sell” rating in a research report on Wednesday, October 1st. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $84.77.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.